RxDoctor Payments Data

Richard Hughes, MD

Otolaryngology · Glens Falls, NYNPI 1427044262

Payments from drug & device makers

$4,555in general payments, 2019–2025

Across 146 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$828
  • Intersect ENT, Inc.$507
  • GSK$463
  • Optinose US, Inc.$435
  • Regeneron Healthcare Solutions, Inc.$391
  • Acclarent, Inc$375
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,555100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,555 in reported general payments places this provider in the 75th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$176,335
Medicare patients
495
Services billed
3,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate20$21,624
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,652
Mometasone Furoate208$13,734
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth115$13,407
Olopatadine Hcl72$7,565
Azelastine Hcl336$6,765
Desloratadine66$2,950
Ipratropium Bromide60$1,731
Fluticasone Propionate80$1,010
Levocetirizine Dihydrochloride109$828
Spironolactone-HctzSpironolact/Hydrochlorothiazid20$733
Omeprazole55$419
Montelukast Sodium45$404
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$381
Ofloxacin12$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$435$21,62420 claims
GSKTrelegy Ellipta$463$14,65223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →